34% of patients) or HFpEF to dapagliflozin or placebo
While dedicated large-scale trials in post-bariatric populations are ongoing, retrospective studies suggest efficacy in patients with weight regain
The American College of Obstetricians and Gynecologists, Breastfeeding Your Baby: Frequently Asked Questions, July 2023 The American College of Obstetricians and Gynecologists, Exercise After Pregnancy, October 2024 The American College of Obstetricians and Gynecologists, Weight Gain During Pregnancy, June 2013 Cleveland Clinic, GLP-1 Agonists, July 2023 Cleveland Clinic, Progestin, March 2023 Current Obesity Reports, Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over, June 2017 Diabetes Care (American Diabetes Association), GLP-1 Receptor Agonists and the Risk of Thyroid Cancer, November 2022 Frontiers in Endocrinology, Effects of GLP-1 Agonists and SGLT2 Inhibitors During Pregnancy and Lactation on Offspring Outcomes: A Systematic Review of the Evidence, October 2023 UCLA Health, Semaglutide for Weight Loss - What You Need to Know US Food and Drug Administration, FDAs Concerns with Unapproved GLP-1 Drugs Used for Weight Loss UT Southwestern Medical Center, 4 Factors That Can Decrease Breast Milk Supplyand How to Replenish It, May 2022 Real-parent perspectives: Kelley D., mom of two in Indiana Learn how we ensure the accuracy of our content through our editorial and medical review process
Ethical Approval Not applicable
We understand that weight management is a complex journey that requires a personalized approach
Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 based therapies: An expert consensus statement using a modified Delphi approach
